These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 7906524)

  • 1. Methodological and design issues in clinical trials of new neuroleptics: an overview.
    Awad AG
    Br J Psychiatry Suppl; 1993 Dec; (22):51-7. PubMed ID: 7906524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical development of atypical antipsychotics: research design and evaluation. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():10-6. PubMed ID: 9766614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose selection and comparator drugs in schizophrenia research.
    Kane JM
    J Clin Psychiatry; 2001; 62 Suppl 9():29-32; discussion 33-4. PubMed ID: 11379828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole: new drug. Just another neuroleptic.
    Prescrire Int; 2005 Oct; 14(79):163-7. PubMed ID: 16285069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Problems in evaluating new antipsychotic drugs].
    Fleischhacker WW
    Wien Med Wochenschr; 1998; 148(11-12):266-72. PubMed ID: 9746969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Methodolocical issues of naturalistic observational studies on the economic evaluation of neuroleptic treatment for schizophrenic disease].
    Kilian R; Angermeyer MC; Becker T
    Gesundheitswesen; 2004 Mar; 66(3):180-5. PubMed ID: 15088222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial design issues in schizophrenic research.
    Casey DE
    J Clin Psychiatry; 2001; 62 Suppl 9():17-20; discussion 21-2. PubMed ID: 11379826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subjective well-being and quality of life under atypical antipsychotic treatment.
    Karow A; Naber D
    Psychopharmacology (Berl); 2002 Jun; 162(1):3-10. PubMed ID: 12107610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New generation antipsychotic drugs and compliance behaviour.
    Voruganti LP; Baker LK; Awad AG
    Curr Opin Psychiatry; 2008 Mar; 21(2):133-9. PubMed ID: 18332660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other.
    Fleischhacker WW; Widschwendter CG
    Curr Opin Psychiatry; 2006 Mar; 19(2):128-34. PubMed ID: 16612191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in schizophrenia.
    Weiss EM; Bilder RM; Fleischhacker WW
    Psychopharmacology (Berl); 2002 Jun; 162(1):11-7. PubMed ID: 12107611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sertindole, a new atypical antipsychotic for the treatment of schizophrenia.
    Brown LA; Levin GM
    Pharmacotherapy; 1998; 18(1):69-83. PubMed ID: 9469684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations.
    Stroup TS; Alves WM; Hamer RM; Lieberman JA
    Nat Rev Drug Discov; 2006 Feb; 5(2):133-46. PubMed ID: 16518380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial.
    Nasrallah HA
    J Clin Psychiatry; 2007; 68 Suppl 1():5-11. PubMed ID: 17286522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia.
    Vohora D
    Curr Opin Investig Drugs; 2007 Jul; 8(7):531-8. PubMed ID: 17659473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Atypical pharmacologic characteristics of an antipsychotic drug: clozapine].
    Gosselin O; Ribeyre JM; Kahn JP
    Encephale; 1997 Sep; 23 Spec No 4():2-6. PubMed ID: 9417400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The statistical comparison of clinical trials.
    Schooler NR
    J Clin Psychiatry; 2001; 62 Suppl 9():35-7; discussion 38-9. PubMed ID: 11379830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotensin receptor agonists and antagonists for schizophrenia.
    Richelson E; Fredrickson PA; Boules MM
    Am J Psychiatry; 2005 Mar; 162(3):633-4; author reply 635. PubMed ID: 15741499
    [No Abstract]   [Full Text] [Related]  

  • 19. Placebo or active control trials of antipsychotic drugs?
    Fleischhacker WW; Czobor P; Hummer M; Kemmler G; Kohnen R; Volavka J
    Arch Gen Psychiatry; 2003 May; 60(5):458-64. PubMed ID: 12742866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and solutions in developing new medications for Schizophrenia.
    J Clin Psychiatry; 2010 Oct; 71(10):1391-9. PubMed ID: 21062617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.